Dimethylamino-acetic acid methyl ester; hydrochloride | 1954-58-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Dimethylamino-acetic acid methyl ester; hydrochloride
• 英文别名: (2-Methoxy-2-oxoethyl)-dimethylazanium;chloride
• CAS: 1954-58-1
• 化学式: C₅H₁₁NO₂*ClH
• 分子量: 153.609
• InChiKey: MDEQIPCZMDWUEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.14
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Dimethylamino-acetic acid methyl ester; hydrochloride 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 1.0h， 生成 N,N-二甲基乙醇胺
  参考文献：
  名称：

  Syntheses of 1,2-di-O-palmitoyl-sn-glycero-3-phosphocholine (DPPC) and analogs with 13C- and 2H-labeled choline head groups

  摘要：

  The syntheses of four head group labeled analogs of 1,2-di-O-palmitoyl-sn-glycero-3-phosphocholine (DPPC) (6) by a general method from 1,2-di-O-palmitoyl-sn-glycero-3-phosphatidic acid (5) have been performed. The syntheses of 1,2-di-O-palmitoyl-sn-glycero-3-phospho[alpha-C-13]choline (6a) and 1,2-di-O-palmitoyl-sn-glycero-3-phospho[beta-C-13]choline (6b) were performed from labeled [1-C-13]glycine (1a) in 52% overall yield and from [2-C-13]glycine (1b) in 56%, overall yield, respectively. 1,2-Di-O-palmitoyl-sn-glycero-3-phospho[N((CH3)-H-2)(3)]choline (9) was prepared from 2-aminoethanol in 39% overall yield. 1,2-Di-O-palmitoyl-sn-glycero-3-phospho[alpha-(CH2)-H-2]choline (12) was prepared from N,N-dimethylglycine ethyl ester in 50% overall yield. (C) 1997 Elsevier Science Ireland Ltd.

  DOI：

  10.1016/s0009-3084(97)02672-8
• 作为产物：
  描述：

  甲醇 、 N,N-二甲基甘氨酸 在 盐酸 作用下， 反应 0.5h， 以73%的产率得到Dimethylamino-acetic acid methyl ester; hydrochloride
  参考文献：
  名称：

  Syntheses of 1,2-di-O-palmitoyl-sn-glycero-3-phosphocholine (DPPC) and analogs with 13C- and 2H-labeled choline head groups

  摘要：

  The syntheses of four head group labeled analogs of 1,2-di-O-palmitoyl-sn-glycero-3-phosphocholine (DPPC) (6) by a general method from 1,2-di-O-palmitoyl-sn-glycero-3-phosphatidic acid (5) have been performed. The syntheses of 1,2-di-O-palmitoyl-sn-glycero-3-phospho[alpha-C-13]choline (6a) and 1,2-di-O-palmitoyl-sn-glycero-3-phospho[beta-C-13]choline (6b) were performed from labeled [1-C-13]glycine (1a) in 52% overall yield and from [2-C-13]glycine (1b) in 56%, overall yield, respectively. 1,2-Di-O-palmitoyl-sn-glycero-3-phospho[N((CH3)-H-2)(3)]choline (9) was prepared from 2-aminoethanol in 39% overall yield. 1,2-Di-O-palmitoyl-sn-glycero-3-phospho[alpha-(CH2)-H-2]choline (12) was prepared from N,N-dimethylglycine ethyl ester in 50% overall yield. (C) 1997 Elsevier Science Ireland Ltd.

  DOI：

  10.1016/s0009-3084(97)02672-8

文献信息

• Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors
  申请人：HALLEY Frank

  公开号：US20090082379A1

  公开（公告）日：2009-03-26

  Compounds of formula (I): wherein Ra, Rb, R, X 1 and X 2 are as defined in the disclosure, pharmaceutical compositions comprising said compounds, processes for making and methods of using the same are provided.

  式(I)的化合物： 其中Ra、Rb、R、X1和X2如所定义，提供了包括所述化合物的药物组合物、制备过程和使用方法。
• N-methyl-2-dimethylaminoacetohydroxamic acid as a new reagent for the selective cleavage of active esters under neutral conditions
  作者：Mitsunori Ono、Isamu Itoh

  DOI：10.1016/s0040-4039(00)95161-x

  日期：1989.1

  A new reagent, N-methyl-2-dimethylaminoacetohydroxamic acid was developed for the selective cleavage of active esters under neutral conditions. The kinetic studies and the applications of are described.

  开发了一种新的试剂N-甲基-2-二甲基氨基乙酰氧肟酸，用于在中性条件下选择性裂解活性酯。描述了动力学研究及其应用。
• 3-Carbamoyl-2-Pyridone Derivative
  申请人：Ishizuka Natsuki

  公开号：US20080103139A1

  公开（公告）日：2008-05-01

  The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R 1 is optionally substituted C1-C8 alkyl and the like; R 2 is C1-C6 alkyl; R 3 is C1-C6 alkyl and the like; or R 2 and R 3 taken together with may form an optionally substituted 5 to 10 membered non-aromatic carbon ring; R 4 is hydrogen and the like; G is a group selected from the groups shown by the formula an the like: wherein R 5 is hydrogen and the like; X 1 is a single bond and the like; X 2 is optionally substituted C1-C8 alkylene that may be replaced by one or two groups of —O—, or —N(R 6 )—, wherein R 6 is hydrogen and the like, and the like; X 3 is a single bond and the like; a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.

  本发明提供了具有激动大麻素受体的作用的化合物，其由式（I）表示：其中，R1是可选取的取代的C1-C8烷基等；R2是C1-C6烷基；R3是C1-C6烷基等；或R2和R3共同形成可选取代的5至10个成员的非芳香碳环；R4是氢等；G是由式等所示的基团中选取的基团：其中，R5是氢等；X1是单键等；X2是可选取代的C1-C8烷基，可以被一或两个-O-或-N（R6）-的基团替代，其中R6是氢等；X3是单键等；其药学上可接受的盐或其溶剂，以及制药组合物、治疗特应性皮炎的制剂和抗瘙痒剂，特别是口服和外用的抗瘙痒剂，每种制剂均以所述化合物为活性成分。
• 3-CARBAMOYL-2-PYRIDONE DERIVATIVES
  申请人：ISHIZUKA Natsuki

  公开号：US20120208813A1

  公开（公告）日：2012-08-16

  The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R 1 , R 2 , R 3 , R 4 , and G are defined as herein, a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.

  本发明提供了具有激动大麻素受体的活性的化合物，该受体由公式（I）表示：其中R1、R2、R3、R4和G如本文所定义，其药学上可接受的盐或溶剂，以及制备该化合物为活性成分的药物组合物、治疗特应性皮炎的药剂和抗瘙痒剂，尤其是用于口服和外用的抗瘙痒剂。
• Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
  申请人：Aventis Pharma S.A.

  公开号：US07935819B2

  公开（公告）日：2011-05-03

  Compounds of formula (I): wherein Ra, Rb, R, X1 and X2 are as defined in the disclosure, pharmaceutical compositions comprising said compounds, processes for making and methods of using the same are provided.

  提供化学式（I）的化合物，其中Ra、Rb、R、X1和X2如披露中所定义，包括该化合物的制药组合物，制备该化合物的方法和使用方法。